Patents by Inventor Matthias Thorolfsson
Matthias Thorolfsson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20150344576Abstract: Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.Type: ApplicationFiled: August 18, 2015Publication date: December 3, 2015Inventors: Alessandro Moretta, Mariella Della Chiesa, Pascale Andre, Laurent Gauthier, Francois Romagne, Peter Andreas Nicolai Reumert Wagtmann, Ivan Svendsen, Stefan Zahn, Anders Svensson, Matthias Thorolfsson, Soren Berg Padkaer, Kristian Kjaergaard, Pieter Johannes Louis Spee, Michael Wilken
-
Publication number: 20150191547Abstract: Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.Type: ApplicationFiled: March 16, 2015Publication date: July 9, 2015Inventors: Alessandro Moretta, Mariella Della Chiesa, Pascale Andre, Laurent Gauthier, Francois Romagne, Peter Andreas Nicolai Reumert Wagtmann, Ivan Svendsen, Stefan Zahn, Anders Svensson, Matthias Thorolfsson, Soren Berg Padkaer, Kristian Kjaergaard, Pieter Johannes Louis Spee, Michael Wilken
-
Patent number: 8981065Abstract: Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.Type: GrantFiled: July 8, 2013Date of Patent: March 17, 2015Assignees: Novo Nordisk A/S—Novo Alle, Innate Pharma S.A.S., University of GenoaInventors: Alessandro Moretta, Mariella Della Chiesa, Pascale Andre, Laurent Gauthier, Francois Romagne, Peter Andreas Nicolai Reumert Wagtmann, Ivan Svendsen, Stefan Zahn, Anders Svensson, Matthias Thorolfsson, Soren Berg Padkaer, Kristian Kjaergaard, Pieter Johannes Louis Spee, Michael Wilken
-
Patent number: 8614307Abstract: Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.Type: GrantFiled: January 11, 2012Date of Patent: December 24, 2013Assignees: Novo-Nordisk A/S—Novo Alle, Innate Pharma S.A.S.Inventors: Alessandro Moretta, Mariella Della Chiesa, Pascale Andre, Laurant Gauthier, Francois Romagne, Peter Andreas Nicolai Reumert Wagtmann, Ivan Svendsen, Stefan Zahn, Anders Svensson, Matthias Thorolfsson, Soren Berg Padkjaer, Kristian Kjaergaard, Petrus Johannes Loius Spee, Milchael Wilken
-
Publication number: 20130287770Abstract: Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.Type: ApplicationFiled: July 8, 2013Publication date: October 31, 2013Inventors: Alessandro Moretta, Mariella Della Chiesa, Pascale Andre, Laurent Gauthier, Francois Romagne, Peter Andreas Nicolai Reumert Wagtmann, Ivan Svendsen, Stefan Zahn, Anders Svensson, Matthias Thorolfsson, Soren Berg Padkaer, Kristian Kjaergaard, Pieter Johannes Loius Spee, Milchael Wilken
-
Publication number: 20120208237Abstract: Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.Type: ApplicationFiled: January 11, 2012Publication date: August 16, 2012Applicants: Innate Pharma S.A.S, Novo-Nordisk A/S - Novo AlleInventors: Alessandro Moretta, Mariella Della Chiesa, Pascale Andre, Laurent Gauthier, Francois Romagné, Peter Andreas Nicolai Reumert Wagtmann, Ivan Svendsen, Stefan Zahn, Anders Svensson, Matthias Thórólfsson, Søren Berg Padkær, Kristian Kjaergaard, Pieter Spee, Michael Wilken
-
Patent number: 8119775Abstract: Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.Type: GrantFiled: October 2, 2008Date of Patent: February 21, 2012Assignees: University of Genoa, Innate Pharma S.A.S., Novo Nordisk A/SInventors: Alessandro Moretta, Mariella Della Chiesa, Pascale Andre, Laurent Gauthier, Francois Romagné, Peter Andreas Nicolai Reumert Wagtmann, Ivan Svendsen, Stefan Zahn, Anders Svensson, Matthias Thórólfsson, Søren Berg Padkær, Kristian Kjaergaard, Pieter Spee, Michael Wilken
-
Publication number: 20090081240Abstract: Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.Type: ApplicationFiled: October 2, 2008Publication date: March 26, 2009Applicants: Novo Nordisk A/S, Innate Pharma, University of GenoaInventors: Alessandro Moretta, Mariella Della Chiesa, Pascale Andre, Laurent Gauthier, Francois Romagne, Peter Andreas Nicolai Reumert Wagtmann, Ivan Svendsen, Stefan Zahn, Anders Svensson, Matthias Thorolfsson, Soren Berg Padkaer, Kristian Kjaergaard, Pieter Spee, Michael Wilken